Acute Rheumatic fever , symp, treatment, management
Reading Document
Medical Text Search
Acute Rheumatic Fever symptoms diagnosis Jones criteria
Medical Text Search
Acute Rheumatic Fever treatment management antibiotics anti-inflammatory
GradeResponse
GradeResponse
Medical Text Search
Acute Rheumatic Fever Jones criteria major minor criteria pathogenesis streptococcal
Medical Text Search
Acute Rheumatic Fever secondary prophylaxis penicillin benzathine duration carditis
Drawing on retrieved content from Harrison's and the Echocardiography in Rheumatic Heart Disease source, supplemented with comprehensive clinical knowledge:
Acute Rheumatic Fever (ARF)
Overview
ARF is a non-suppurative, inflammatory complication of pharyngeal infection with Group A Streptococcus pyogenes (GAS). It primarily affects children aged 5–15 years and is the leading cause of acquired heart disease in low- and middle-income countries. The pathogenesis involves molecular mimicry — streptococcal M-protein antigens share epitopes with cardiac tissue, triggering an autoimmune response.
Diagnosis — Revised Jones Criteria (2015)
Diagnosis requires evidence of preceding GAS infection PLUS:
- 2 major criteria, OR
- 1 major + 2 minor criteria
For low-risk populations (ARF incidence <2/100,000/year), stricter thresholds apply.
Major Criteria
| Criterion | Details |
|---|---|
| Carditis (clinical) | Pancarditis — endocarditis (valvulitis), myocarditis, pericarditis; new murmur of mitral/aortic regurgitation |
| Carditis (subclinical) | Echocardiographic valvulitis without auscultatory findings — recognized as a major criterion since 2015 |
| Migratory Polyarthritis | Large joints (knees, ankles, elbows, wrists); painful, asymmetric, migratory; responds dramatically to aspirin |
| Sydenham's Chorea | Involuntary, purposeless movements; emotional lability; may appear weeks–months after strep infection |
| Erythema Marginatum | Pink-red, non-pruritic rash with central clearing; evanescent, worsens with heat; seen on trunk/limbs |
| Subcutaneous Nodules | Firm, painless nodules over bony prominences (elbows, knees, spine); associated with severe carditis |
Polyarthralgia counts as a major criterion (in place of arthritis) only in moderate/high-risk populations when other criteria are absent.
Minor Criteria
| Criterion | Details |
|---|---|
| Fever | ≥38.5°C |
| Elevated ESR | ≥60 mm/hr (low-risk) / ≥30 mm/hr (mod/high-risk) |
| Elevated CRP | ≥3.0 mg/dL |
| Prolonged PR interval | On ECG (corrected for age/heart rate) |
| Polyarthralgia | In low-risk populations only |
Evidence of Preceding GAS Infection (Required)
- Positive throat culture or rapid antigen test
- Elevated or rising ASO titer (antistreptolysin O)
- Elevated or rising anti-DNase B
- Recent documented streptococcal pharyngitis
Role of Echocardiography
Echo is mandatory in all suspected ARF cases. Subclinical carditis (pathological valvular regurgitation on echo without clinical signs) is a major criterion — mild/moderate regurgitation can be missed on auscultation alone. Echo also establishes baseline severity, which determines prophylaxis duration. (Use of Echocardiography in Rheumatic Heart Disease, p. 3)
Clinical Features (Symptoms)
Arthritis (Most Common ~75%)
- Classically migratory polyarthritis affecting large joints
- Exquisitely tender; often disproportionate to visible swelling
- Responds rapidly and dramatically to salicylates (response so dramatic it is almost diagnostic)
Carditis (~50–60%)
- Most serious manifestation; may be subclinical
- Mitral regurgitation most common; aortic regurgitation also seen
- Pancarditis can cause heart failure, pericardial rub, cardiomegaly
- Rheumatic heart disease (RHD) is the long-term sequela
Chorea (10–30%)
- Delayed by weeks to months after GAS infection
- May occur in isolation ("pure chorea") without other features
- More common in girls; emotional lability is characteristic
Erythema Marginatum (<10%)
- Fleeting rash; appears/disappears over hours
- Located on trunk and proximal limbs, never on face
Subcutaneous Nodules (<5%)
- Strongly associated with significant carditis
- Persist for weeks
Investigations
| Test | Purpose |
|---|---|
| CBC | Leukocytosis during active inflammation |
| ESR, CRP | Acute phase reactants — monitor disease activity |
| ASO titer, anti-DNase B | Evidence of prior GAS infection |
| Throat culture | Identify/treat active GAS carriage |
| ECG | PR prolongation, signs of pericarditis |
| Echocardiogram | Diagnose/grade carditis; subclinical valvulitis |
| Chest X-ray | Cardiomegaly, pulmonary edema in severe carditis |
Treatment & Management
(Harrison's Principles of Internal Medicine, 21st ed., p. 10075)
1. Eradication of GAS (Primary Treatment)
Even if throat culture is negative, treat to eliminate residual streptococci:
| Drug | Dose | Duration |
|---|---|---|
| Benzathine penicillin G (preferred) | 600,000 U IM (<27 kg); 1.2 million U IM (≥27 kg) | Single dose |
| Amoxicillin | 50 mg/kg/day (max 1 g/day) PO | 10 days |
| Phenoxymethylpenicillin (Pen V) | 250 mg BD–TDS PO | 10 days |
| Erythromycin (penicillin allergy) | Age-appropriate dose | 10 days |
2. Anti-inflammatory Therapy
Arthritis / Fever (without significant carditis)
- Aspirin: 80–100 mg/kg/day in 4–5 divided doses (children); 4–8 g/day (adults)
- Response within 1–2 days is near-diagnostic; taper after 2 weeks
- Monitor for salicylate toxicity (tinnitus, hyperventilation)
- Naproxen: an alternative NSAID with comparable efficacy and better tolerability
Carditis (moderate to severe / heart failure)
- Corticosteroids (prednisolone) are added:
- Dose: 1–2 mg/kg/day (max 80 mg/day) for 2–4 weeks, then taper
- Use when carditis is severe or causing hemodynamic compromise
- Overlap with aspirin during taper to prevent rebound
- Note: Steroids do not prevent the development of RHD
Sydenham's Chorea
- Often self-limiting (weeks to months)
- Valproic acid (first-line): controls choreiform movements
- Carbamazepine: alternative
- Haloperidol or pimozide: for refractory chorea
- Minimize stimulation; quiet environment
3. Heart Failure Management
- Diuretics (furosemide), ACE inhibitors, digoxin as needed
- Bed rest during active carditis
- Fluid and sodium restriction
4. Bed Rest
- Strict bed rest during acute phase, especially with carditis
- Graded mobilization as inflammation resolves (guided by ESR/CRP normalization)
Secondary Prophylaxis (Critical)
The goal is prevention of recurrent GAS pharyngitis, which worsens valvular disease with each episode.
| Drug | Dose & Route | Frequency |
|---|---|---|
| Benzathine penicillin G (preferred) | 1.2 million U IM | Every 3–4 weeks |
| Phenoxymethylpenicillin | 250 mg PO BD | Daily |
| Sulfadiazine / Sulfamethoxazole | 0.5 g (<30 kg) or 1 g (≥30 kg) PO | Daily |
| Erythromycin (penicillin + sulfa allergy) | 250 mg PO BD | Daily |
Duration of Secondary Prophylaxis
| Clinical Situation | Duration |
|---|---|
| ARF without carditis | 5 years or until age 21 (whichever is longer) |
| ARF with carditis, no residual valvular disease | 10 years or until age 21 |
| ARF with carditis + persistent valvular disease (RHD) | At least 10 years or until age 40 (sometimes lifelong) |
| Severe RHD / post-valve surgery | Lifelong |
Benzathine penicillin IM every 3–4 weeks is superior to oral regimens due to adherence. In high-risk settings (crowding, poor access), every-3-week dosing is preferred.
Complications
- Rheumatic Heart Disease (RHD): Mitral stenosis (most common chronic lesion), mitral regurgitation, aortic regurgitation
- Infective endocarditis risk with underlying valvular disease
- Atrial fibrillation from mitral stenosis
- Pulmonary hypertension in advanced RHD
- Rebound inflammation after stopping anti-inflammatory therapy too quickly
Prognosis
- Without carditis: complete recovery; main risk is recurrence with subsequent GAS infection
- With carditis: risk of RHD proportional to severity and number of recurrent episodes
- Key message: secondary prophylaxis compliance is the single most important determinant of long-term outcome
Sources: Harrison's Principles of Internal Medicine, 21st ed. (p. 10075) | Use of Echocardiography in the Evaluation of Rheumatic Heart Disease (p. 3) | AHA/WHO ARF Guidelines
This is a shared conversation. Sign in to Orris to start your own chat.